APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

About

Brief Summary

The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.

Study Type

Observational

Eligibility

Gender

All

Healthy Volunteers

Minimum Age

N/A

Maximum Age

N/A

Inclusion Criteria for Living Donors:

Living kidney donors with self-reported recent African ancestry (defined as African American, Afro-Caribbean, Hispanic black or African) will be eligible for inclusion.

Exclusion Criteria for Living Donors:

Participants who are unable or unwilling to provide informed consent.

Inclusion Criteria for Recipients:

Recipients of a kidney transplant from an eligible living or deceased donor with recent African ancestry.
Recipients of multi-organ transplants including a kidney plus an additional organ (i.e. liver, heart, lung, pancreas, etc.) or pediatric en bloc and dual kidney transplants.

Exclusion Criteria for Recipients:

Participants who are unable or unwilling to provide informed consent.

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you